Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$69.80 USD
+0.87 (1.26%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $69.80 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.80 USD
+0.87 (1.26%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $69.80 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum D VGM
Zacks News
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Exact Sciences (EXAS) Q4 Earnings Top Estimates, Margin Falls
by Zacks Equity Research
Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences (EXAS) Q4 top line.
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 20% and 6.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) fourth-quarter top line.
5 Large-Cap Stocks Set to Beat on Q4 Earnings This Week
by Nalak Das
The following five large-cap stocks are set to beat Q4 earnings estimates this week. These are: TECK, LECO, NI, EXAS and GFL.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Earnings Season Could Be Great for Exact Sciences (EXAS)
by Zacks Equity Research
Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences (EXAS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed at $65.52 in the latest trading session, marking a +0.17% move from the prior day.
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMN Healthcare (AMN) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AMN Healthcare's (AMN) fourth-quarter results are likely to reflect soft demand across the majority of its segments.
Insulet (PODD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
In Drug Delivery, Insulet (PODD) is expected to have faced higher manufacturing costs in Q4.
Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) fourth-quarter results are likely to reflect continued strength in its Global Industrial segment.
Exact Sciences (EXAS) Stock Moves -1.09%: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed the most recent trading day at $67.82, moving -1.09% from the previous trading session.
Exact Sciences (EXAS) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
3 MedTech Stocks Likely to Beat Estimates This Earnings Season
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.
Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Continued increase in Cologuard volume is likely to have benefited Exact Sciences (EXAS) Q4 performance.
Exact Sciences (EXAS) Stock Moves -0.46%: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed the most recent trading day at $67.14, moving -0.46% from the previous trading session.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Exact Sciences (EXAS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed the most recent trading day at $66.21, moving -1.88% from the previous trading session.
Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Exact Sciences (EXAS) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Here's How Much a $1000 Investment in Exact Sciences Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Exact Sciences (EXAS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed at $67.82 in the latest trading session, marking a -0.6% move from the prior day.
Exact Sciences (EXAS) Stock Moves -0.67%: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed at $67.92 in the latest trading session, marking a -0.67% move from the prior day.